CAMBRIDGE, Mass.--(BUSINESS WIRE)--Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its thirteenth fund, raising $450 million in an oversubscribed fundraise. With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to create and invest in a new set of biotech companies aimed at delivering impactful medicines to patients.
“Over the past two years, we have all experienced the tremendous benefits of investment in scientific and medical innovation,” said Jason Rhodes, partner at Atlas Venture. “We are deeply appreciative of the ongoing support of our LPs, which enables us to continue our disciplined venture creation approach to building and scaling biotech companies advancing novel therapeutics for a wide range of serious diseases.”
Atlas Venture collaborates with experienced venture partners and entrepreneurs-in-residence to found, seed, incubate, and invest in new biotech startups. Taking a global view of scientific innovation, Atlas-backed companies are formed from breakthrough discoveries and technologies from institutions and researchers around the world. Atlas-built companies are shaped according to the unique scientific opportunity of each, resulting in a mix of platform and asset-centric companies, all focused on the goal of creating transformational new medicines.
Atlas Venture has been building and investing in innovative biotech startups for more than two decades. Since 2015, Atlas Venture has raised over $2 billion and has created and/or invested in over 50 biotech companies. In addition to Fund XIII, Atlas is also investing from Opportunity Fund II, a $300 million fund raised in 2021 to support portfolio companies as they raise subsequent financings and advance therapeutic programs. Alongside Rhodes, the six investing partners in Fund XIII also include Kevin Bitterman, Bruce Booth, Jean-François Formela, Michael Gladstone, and David Grayzel.
About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.
